Toru Kiguchi

Toru Kiguchi

Auto-generated profile, based on publicly available information

Toru Kiguchi

Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
YNYasuhito Nannya
Yasuhito Nannya
MTMagnus Tobiasson
Magnus Tobiasson
SSShinya Sato
Shinya Sato
EBElsa Bernard
Elsa Bernard
SOShigeki Ohtake
Shigeki Ohtake
SOSeishi Ogawa
Seishi Ogawa
Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)–related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their posttreatment clone size. We enrolled a total of 449 patients with MDS or related myeloid neoplasms. They were analyzed for gene mutations in pretreatment (n = 449) and posttreatment (n = 289) bone marrow samples using targeted-capture sequencing to assess the impact of gene mutations and their posttreatment clone size on treatment outcomes. In Cox proportional hazard modeling, multihit TP53 mutation (hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.42-2.91; P < .001), EZH2 mutation (HR, 1.71; 95% CI, 1.14-2.54; P = .009), and DDX41 mutation (HR, 0.33; 95% CI, 0.17-0.62; P < .001), together with age, high-risk karyotypes, low platelets, and high blast counts, independently predicted OS. Posttreatment clone size accounting for all drivers significantly correlated with International Working Group (IWG) response (P < .001, using trend test), except for that of DDX41-mutated clones, which did not predict IWG response. Combined, IWG response and posttreatment clone size further improved the prediction of the original model and even that of a recently proposed molecular prediction model, the molecular International Prognostic Scoring System (IPSS-M; c-index, 0.653 vs 0.688; P < .001, using likelihood ratio test). In conclusion, evaluation of posttreatment clone size, together with the pretreatment mutational profile as well as the IWG response play a role in better prognostication of azacitidine-treated patients with myelodysplasia.

27 July 2018 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
YMYusuke Meguri
Yusuke Meguri
NANoboru Asada
Noboru Asada
YNYukio Nakasako
Yukio Nakasako
EKEisei Kondo
Eisei Kondo
YKYui Kambara
Yui Kambara
TKToru Kiguchi
Toru Kiguchi

13 August 2001 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TKToru Kiguchi
Toru Kiguchi
KNKenji Niiya
Kenji Niiya
MSMisako Shibakura
Misako Shibakura
TMTakayoshi Miyazono
Takayoshi Miyazono
KSKatsuji Shinagawa
Katsuji Shinagawa
MHMine Harada
Mine Harada
Current evidence has suggested the possible involvement of ROS as signaling messengers in IL-1β- or LPS-induced gene expression. We previously reported that both IL-1β and LPS induce uPA in RC-K8 human lymphoma cells. Here, we provide evidence that ROS-generating anthracycline antibiotics, including doxorubicin and aclarubicin, upregulate uPA expression in 2 human malignant cell lines, RC-K8 and H69 small-cell lung-carcinoma cells. Both doxorubicin and aclarubicin markedly increased uPA accumulation in RC-K8- and H69-conditioned medium in a dose-dependent manner. In each case, maximal induction was observed at a sublethal concentration, i.e., at a concentration where cell growth was slightly inhibited. Both doxorubicin and aclarubicin increased uPA mRNA levels, and induction in each case reached the maximal level 9 hr after stimulation. Doxorubicin barely changed the half-life of uPA mRNA and activated uPA gene transcription. Antioxidants such as NAC and PDTC inhibited doxorubicin-induced uPA mRNA accumulation. Microarray analysis, using Human Cancer CHIP version 2 (Takara Shuzo, Kyoto, Japan), in which 425 human cancer-related genes were spotted on glass plates, revealed that uPA is 1 of 3 genes that were clearly upregulated in H69 cells by doxorubicin stimulation. These findings suggest that the anthracycline induces uPA in human malignant cells by activating gene transcription in which ROS may be involved. Therefore, by upregulating uPA expression, the anthracycline may influence many biologic cell functions mediated by the uPA/plasmin system.

4 March 2022 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
KMKayoko Murayama
Kayoko Murayama
TKToru Kiguchi
Toru Kiguchi
KIKoji Izutsu
Koji Izutsu
YKYoshihiro Kameoka
Yoshihiro Kameoka
MHMichihiro Hidaka
Michihiro Hidaka
YTYasuhito Terui
Yasuhito Terui
This single-arm phase 3 study was conducted to confirm the results of our phase 2 study of bendamustine (B)-rituximab (R) in patients with relapsed/refractory diffuse large B cell lymphoma (rrDLBCL). The primary endpoint was overall response rate (ORR). Autologous stem cell transplantation-ineligible rrDLBCL patients with ≤ 2 prior chemotherapy regimens received R 375 mg/m2 IV on day 1 and B 120 mg/m2/day IV on days 2 and 3 every 21 days up to 6 cycles. Thirty-eight patients with a median age of 74 years (range, 43–86) received BR. The ORR and complete response rates were 76.3% and 47.4%, respectively. With a median follow-up of 19.5 months including long-term follow-up, median progression-free survival was 11.9 months. Median OS was 29.2 months. Discontinuation of treatment due to Gr3-5 TEAE was observed among 13 of 38 patients (34.2%). One patient with cytomegalovirus enterocolitis died during follow-up. This BR regimen was confirmed to be effective and tolerable in studied patients. ClinicalTrials.gov Identifier: NCT03372837 registered on 14 December 2017, NCT04354402 registered on 21 April, 2020.

1 February 2010 in Leukemia Research
Verified
Journal Article
Closed access
SYSeiichiro Yoshizawa
Seiichiro Yoshizawa
MGMoritaka Gotoh
Moritaka Gotoh
TKToshihiko Kitahara
Toshihiko Kitahara
TKToru Kiguchi
Toru Kiguchi
DADaigo Akahane
Daigo Akahane
KOKazuma Ohyashiki
Kazuma Ohyashiki

22 October 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
TKToru Kiguchi
Toru Kiguchi
MYMasaki Yamaguchi
Masaki Yamaguchi
NTNaoki Takezako
Naoki Takezako
SMShuichi Miyawaki
Shuichi Miyawaki
KMKoichi Masui
Koichi Masui
TNTomoki Naoe
Tomoki Naoe